VectorBuilder Gene Delivery Seminar Series

The development of safe, effective, and scalable cell and gene therapy (CGT) products remains a critical challenge as the field advances toward increasingly complex therapeutic landscapes. It is now understood that a large portion of Chemistry, Manufacturing, and Controls (CMC) issues come from poor manufacturability challenges as a result of under-optimized vectors obtained from a variety of sources.

To address these challenges, VectorBuilder has introduced CliniVec™, a proprietary consultation service designed to revolutionize CGT workflows by integrating customized vector design, service designed to revolutionize CGT workflows by integrating customized vector design, optimization, and characterization to enable seamless progression from early-stage research to preclinical and clinical development. Drawing from insights in vector construction and characterization (>1 million vectors designed) over the past decade, VectorBuilder highlights key considerations for designing vectors that meet the complex requirements of preclinical and clinical studies. The cliniVec approach aims to provide a comprehensive framework for advancing CGT development through enhanced design and characterization strategies that prioritize safety, performance, and scalability throughout the entire lifecycle of any CGT viral vector.